6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60

Description

6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60

6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60 is a bulk presentation labelled as containing 20mg per unit, with 60 units per pack. Across six packs, this represents 360 labelled units in total.

The name GW50516 is commonly associated with GW501516, also known as Cardarine or Endurobol. It is an experimental compound that acts primarily as a PPAR-delta (PPARβ/δ) agonist. Despite its frequent appearance alongside SARMs, GW501516 is not a SARM.

GW501516 has been investigated in laboratory and animal research involving metabolism, lipid utilisation and exercise-related pathways. It has not been established as a UK-authorised medicine for routine human use.

The exact identity, purity, concentration and formulation of the specific Pharmaqo product should be verified from its original packaging and batch documentation.

Classification

Product: 6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60
Common compound associated with the name: GW501516 (Cardarine)
Category: Experimental PPAR-delta agonist
Labelled strength: 20mg per unit
Pack size: 60 units
Bulk quantity: 6 packs / 360 labelled units

The spelling GW50516 appears in the supplied product name. GW501516 is the compound commonly referred to as Cardarine, so the exact product identity should be verified before making product-specific claims.

What is Pharmaqo GW50516 (CARDARINE) 20mg x 60?

GW501516 is an experimental small molecule developed for research into metabolic and cardiovascular pathways. It acts on PPAR-delta, a nuclear receptor involved in regulating genes associated with lipid metabolism, energy utilisation and skeletal-muscle physiology.

Cardarine became particularly well known through research examining endurance-related metabolic effects. However, these experimental findings do not establish the compound as a safe or effective human performance-enhancing treatment.

The product should therefore be regarded as an investigational compound, rather than as a conventional pharmaceutical medicine or nutritional supplement.

Dosage

There is no established UK-authorised human dosage regimen for Pharmaqo GW50516 (CARDARINE) 20mg x 60.

Experimental research protocols should not be converted into a self-directed human dosing schedule. The labelled 20mg strength is a product specification and should not be interpreted as a recommended dose.

In particular, GW501516 should not be used as the basis for a self-directed endurance, fat-loss or performance-enhancement protocol.

How Does GW50516 (CARDARINE) Work?

GW501516 primarily acts as an agonist of PPAR-delta, a nuclear receptor involved in regulating metabolic gene expression.

Activation of PPAR-delta can influence pathways associated with:

• Fatty-acid utilisation
• Energy metabolism
• Lipid handling
• Skeletal-muscle metabolism
• Exercise-related metabolic adaptation

This mechanism differs from that of SARMs, which primarily act through androgen receptors. Cardarine therefore should not be described as a SARM simply because it is sometimes sold alongside SARM products.

Potential Benefits

Research involving GW501516 has investigated potential effects relating to:

• Fatty-acid metabolism
• Energy utilisation
• Lipid metabolism
• Exercise-related metabolic pathways
• Endurance-associated physiological processes

These findings are experimental and do not represent established clinical benefits.

Cardarine should not be promoted as a proven treatment for weight loss, endurance, athletic performance, cholesterol disorders or metabolic disease.

When Should You Not Take GW50516 (CARDARINE)?

Because GW501516 is an experimental compound without an established routine human therapeutic indication, individuals should not use it as a substitute for approved medical treatment.

Particular caution is appropriate for people with:

• A history of cancer
• Liver disease
• Cardiovascular disease
• Metabolic disorders
• Abnormal lipid levels
• Endocrine disorders
• Pregnancy or breastfeeding
• A history of unexplained adverse reactions to experimental compounds

Anyone receiving treatment for a medical condition should discuss potential exposure to investigational compounds with a qualified healthcare professional.

Mechanism

GW501516 activates PPAR-delta, a receptor that regulates transcription of genes involved in lipid and energy metabolism.

PPAR-delta activation can influence cellular pathways involved in fatty-acid oxidation and energy utilisation. This has made the compound of interest in research into metabolic disorders and exercise physiology.

Its mechanism is fundamentally different from anabolic steroids and SARMs. It does not primarily work by stimulating the androgen receptor.

Uses

GW501516 has been investigated experimentally in areas including:

• Lipid metabolism
• Energy metabolism
• Cardiovascular research
• Skeletal-muscle metabolism
• Exercise physiology
• Metabolic disease research

It does not have an established routine therapeutic use in UK clinical practice.

The specific Pharmaqo product should not be represented as an approved treatment for fat loss, endurance improvement, bodybuilding, diabetes, cholesterol management or athletic performance.

Warnings and Precautions

The principal concern with GW501516 is its experimental safety profile.

Preclinical research raised significant safety concerns, including findings involving tumour development in animal studies at certain exposures. These findings are an important reason the compound should not be treated as an established human medicine.

The long-term effects of GW501516 exposure in humans have not been adequately established.

Commercial research products may also vary in purity, concentration and composition. Incorrect labelling or contamination can introduce additional risks.

Side Effects

Because GW501516 has not undergone the level of clinical development required for routine human treatment, its complete human adverse-effect profile remains uncertain.

Potential concerns include:

• Unknown long-term effects
• Potential effects on liver function
• Metabolic changes
• Changes in lipid metabolism
• Drug interactions
• Effects associated with PPAR-delta signalling
• Potential tumour-related safety concerns based on preclinical findings

Anyone experiencing unexpected or significant symptoms after exposure should seek appropriate medical advice.

Storage

Store 6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60 according to the manufacturer’s original storage instructions.

Keep the product:

• In its original packaging
• Away from excessive heat and direct sunlight
• In a dry environment
• Away from children and unauthorised access

Do not use the product if the packaging is damaged or the identity and integrity of the contents cannot be established.

Where to Buy 6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60?

To get 6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60 online, go to Steroid Sanctuary today to get the best deal on this medicine.

Frequently Asked Questions

1. What is Pharmaqo GW50516 (CARDARINE)?

The supplied product name refers to Cardarine, a name commonly associated with GW501516, an experimental PPAR-delta agonist. The spelling GW50516 should be verified against the original product documentation because GW501516 is the commonly recognised compound designation.

2. How many units are included in 6 x Pharmaqo GW50516 (CARDARINE) 20mg x 60?

Each pack contains 60 labelled units. Six packs therefore provide 360 labelled units in total, with a stated strength of 20mg per unit.

3. Is Cardarine a SARM?

No. Cardarine is generally classified as a PPAR-delta agonist, not a selective androgen receptor modulator. Its mechanism is therefore different from compounds such as LGD-4033 or MK-2866.

4. Is GW501516 approved for human use?

GW501516 is an experimental compound and does not have an established routine therapeutic use as a UK-authorised medicine. Research findings should not be presented as proof of clinical safety or efficacy.

5. Why is caution important with Cardarine?

Long-term human safety has not been adequately established, while preclinical research has raised significant safety concerns. Consequently, Cardarine should not be treated as a conventional supplement or established performance-enhancing medicine.